{"id":"bacillus-calmette-gu-rin-bcg","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Dysuria (painful urination)"},{"rate":"40-60","effect":"Urinary frequency"},{"rate":"20-40","effect":"Hematuria (blood in urine)"},{"rate":"10-20","effect":"Fever"},{"rate":"10-20","effect":"Malaise/fatigue"},{"rate":"<1","effect":"BCG sepsis (rare but serious)"}]},"_chembl":{"chemblId":"CHEMBL2108905","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCG works by activating innate and adaptive immune responses through pattern recognition receptors on immune cells. When instilled directly into the bladder, it triggers local inflammation and recruitment of immune cells that target bladder cancer cells. This immunotherapy approach has been the gold standard for non-muscle-invasive bladder cancer for decades.","oneSentence":"BCG is a live attenuated mycobacterial vaccine that stimulates the immune system to recognize and destroy cancer cells, particularly in the bladder.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:26.639Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-muscle-invasive bladder cancer (NMIBC), including carcinoma in situ"},{"name":"High-grade urothelial carcinoma of the bladder"}]},"trialDetails":[{"nctId":"NCT05037279","phase":"PHASE3","title":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","status":"RECRUITING","sponsor":"Verity Pharmaceuticals Inc.","startDate":"2024-04-24","conditions":"Bladder Cancer, Bladder Cancer Recurrent, Neoplasm Recurrence","enrollment":540},{"nctId":"NCT05714202","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-23","conditions":"Bladder Cancer","enrollment":1135},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":272},{"nctId":"NCT04640623","phase":"PHASE2","title":"A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-18","conditions":"Urinary Bladder Neoplasms","enrollment":220},{"nctId":"NCT06919965","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-09-10","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":220},{"nctId":"NCT05644041","phase":"PHASE2","title":"Intravesical Gem/Doce in Patients With NMIBC","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-03-01","conditions":"Urinary Bladder Cancer","enrollment":25},{"nctId":"NCT04172675","phase":"PHASE2","title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-02-28","conditions":"Urinary Bladder Neoplasms","enrollment":107},{"nctId":"NCT04453293","phase":"PHASE3","title":"Immunization With BCG Vaccine to Prevent Tuberculosis Infection","status":"TERMINATED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2021-12-01","conditions":"Tuberculosis Infection","enrollment":16},{"nctId":"NCT04630730","phase":"PHASE2","title":"Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2022-06-24","conditions":"Bladder Cancer","enrollment":46},{"nctId":"NCT06747455","phase":"PHASE3","title":"BCG for Therapeutic Use Phase Ⅲ Clinical Trial","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-04-08","conditions":"BCG","enrollment":438},{"nctId":"NCT04507126","phase":"PHASE2","title":"A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-03-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT02081326","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2015-06","conditions":"Diabetes Mellitus, Type One, Diabetes Mellitus, Type I, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05180591","phase":"PHASE2","title":"Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-03-22","conditions":"Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05866536","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-05-04","conditions":"Diabetes Mellitus, Type 1 Diabetes, Diabetes type1","enrollment":100},{"nctId":"NCT03504163","phase":"PHASE2","title":"Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-27","conditions":"Bladder Cancer","enrollment":45},{"nctId":"NCT06829823","phase":"PHASE2","title":"Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":20},{"nctId":"NCT07207824","phase":"PHASE3","title":"DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-12-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, NMIBC","enrollment":182},{"nctId":"NCT04149574","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2020-01-15","conditions":"Urinary Bladder Neoplasms","enrollment":13},{"nctId":"NCT06351904","phase":"PHASE1","title":"A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy","status":"RECRUITING","sponsor":"Ractigen Therapeutics.","startDate":"2024-04-03","conditions":"Non-Muscle-Invasive Bladder Cancer (NMIBC)","enrollment":72},{"nctId":"NCT05507671","phase":"PHASE3","title":"The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2021-05-27","conditions":"COVID-19","enrollment":556},{"nctId":"NCT07064863","phase":"PHASE1, PHASE2","title":"A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.","status":"NOT_YET_RECRUITING","sponsor":"Queen's University","startDate":"2025-08-01","conditions":"NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma, Bladder (Urothelial, Transitional Cell) Cancer","enrollment":31},{"nctId":"NCT04179162","phase":"PHASE1, PHASE2","title":"Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-11-22","conditions":"Non-Muscle Invasive Bladder Cancer (NMIBC)","enrollment":54},{"nctId":"NCT05004688","phase":"PHASE2","title":"A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD","status":"COMPLETED","sponsor":"Steven E Arnold, MD","startDate":"2022-03-25","conditions":"Mild Cognitive Impairment, Mild Dementia, Moderate Dementia","enrollment":15},{"nctId":"NCT06889623","phase":"NA","title":"Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-06-01","conditions":"NMIBC","enrollment":72},{"nctId":"NCT03317158","phase":"PHASE1, PHASE2","title":"Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder","status":"RECRUITING","sponsor":"Noah Hahn, M.D.","startDate":"2017-11-21","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":55},{"nctId":"NCT04806178","phase":"PHASE3","title":"Immunological Response of Bladder Cancer Patients Under BCG","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2021-09-03","conditions":"Bladder Cancer, Bacillus Calmette-Guerin","enrollment":30},{"nctId":"NCT03888924","phase":"PHASE2","title":"Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)","status":"RECRUITING","sponsor":"S. Andrea Hospital","startDate":"2019-06-17","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT06636682","phase":"PHASE2","title":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Cellvax Therapeutics Inc","startDate":"2024-10-14","conditions":"Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers","enrollment":100},{"nctId":"NCT04348370","phase":"PHASE4","title":"BCG Vaccine for Health Care Workers as Defense Against COVID 19","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2020-04-20","conditions":"Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere","enrollment":659},{"nctId":"NCT04327206","phase":"PHASE3","title":"BCG Vaccination to Protect Healthcare Workers Against COVID-19","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2020-03-30","conditions":"Coronavirus Disease 2019 (COVID-19), Respiratory Illness, Corona Virus Infection","enrollment":6828},{"nctId":"NCT06441110","phase":"PHASE3","title":"Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2023-06-01","conditions":"Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active","enrollment":76},{"nctId":"NCT05397678","phase":"PHASE4","title":"Trial to Compare BCG-Bulgaria and BCG-Denmark","status":"UNKNOWN","sponsor":"Bandim Health Project","startDate":"2022-10-21","conditions":"Death; Neonatal, Death, Infant, Morbidity;Newborn","enrollment":15000},{"nctId":"NCT06178666","phase":"NA","title":"A Controlled Human Infection Model (CHIM) With Intradermal BCG in Malawi","status":"UNKNOWN","sponsor":"Liverpool School of Tropical Medicine","startDate":"2024-03-01","conditions":"Tuberculosis","enrollment":30},{"nctId":"NCT03246230","phase":"NA","title":"Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2017-09-06","conditions":"Newborn Vaccine Immunogenicity","enrollment":911},{"nctId":"NCT06153849","phase":"","title":"Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2023-12-01","conditions":"Bladder Cancer","enrollment":100},{"nctId":"NCT05820594","phase":"NA","title":"Using BCG Vaccine to Understand Tuberculosis Infection","status":"UNKNOWN","sponsor":"Liverpool School of Tropical Medicine","startDate":"2023-06-30","conditions":"Tuberculosis","enrollment":30},{"nctId":"NCT05004038","phase":"PHASE2","title":"BCG Vaccination Effect on Latent Reservoir Size in Treated HIV-1 Infection:","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2022-01-04","conditions":"HIV-1-infection","enrollment":60},{"nctId":"NCT02281383","phase":"PHASE2","title":"Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-10","conditions":"Bladder Cancer, High Risk Superficial","enrollment":80},{"nctId":"NCT01838200","phase":"PHASE1","title":"Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma","status":"TERMINATED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2014-03","conditions":"Metastatic Melanoma","enrollment":5},{"nctId":"NCT04537663","phase":"PHASE4","title":"Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-07","conditions":"Respiratory Tract Infections, Covid19","enrollment":6112},{"nctId":"NCT02901548","phase":"PHASE2","title":"Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-02-16","conditions":"Carcinoma in Situ of Bladder, Bladder Cancer","enrollment":17},{"nctId":"NCT04328441","phase":"PHASE3","title":"Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-03-25","conditions":"COVID-19","enrollment":1511},{"nctId":"NCT04379336","phase":"PHASE3","title":"BCG Vaccination for Healthcare Workers in COVID-19 Pandemic","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2020-05-04","conditions":"COVID-19, Sars-CoV2","enrollment":1000},{"nctId":"NCT03091764","phase":"","title":"Evaluation of a Patient-Reported Symptom Index for NMIBC","status":"COMPLETED","sponsor":"University of Sydney","startDate":"2016-07-01","conditions":"Superficial Bladder Cancer","enrollment":498},{"nctId":"NCT04414267","phase":"PHASE4","title":"Bacillus Calmette-guérin Vaccination to Prevent COVID-19","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2020-05-26","conditions":"COVID-19, Virus Diseases, Corona Virus Infection","enrollment":301},{"nctId":"NCT03664869","phase":"PHASE3","title":"Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2018-10-26","conditions":"Bladder Cancer","enrollment":300},{"nctId":"NCT04723121","phase":"NA","title":"Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2013-03-01","conditions":"Bladder Cancer","enrollment":204},{"nctId":"NCT03296423","phase":"PHASE4","title":"Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2017-09-21","conditions":"Infection, Hospitalization, Mortality","enrollment":200},{"nctId":"NCT03213405","phase":"PHASE1","title":"A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2017-06-27","conditions":"Respiratory Syncytial Virus Infections","enrollment":24},{"nctId":"NCT04384549","phase":"PHASE3","title":"Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-05-20","conditions":"Infection, Viral, Agent as Cause of Disease Classified Elsewhere","enrollment":1120},{"nctId":"NCT04417335","phase":"PHASE4","title":"Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2020-04-16","conditions":"COVID-19","enrollment":2014},{"nctId":"NCT03335059","phase":"PHASE3","title":"Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.","status":"TERMINATED","sponsor":"Medical Enterprises Ltd.","startDate":"2019-04-04","conditions":"Bladder Cancer, Bladder Neoplasm, Bladder Tumors","enrollment":5},{"nctId":"NCT04319263","phase":"NA","title":"Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2020-03-01","conditions":"Bladder Cancer","enrollment":1600},{"nctId":"NCT02010203","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT","status":"TERMINATED","sponsor":"Heat Biologics","startDate":"2013-12","conditions":"Bladder Cancer","enrollment":104},{"nctId":"NCT00396370","phase":"PHASE1","title":"BCG Vaccination Delivered Intradermally, Orally and by Combined Routes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-12-02","conditions":"Tuberculosis","enrollment":69},{"nctId":"NCT02075203","phase":"PHASE2","title":"Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents","status":"COMPLETED","sponsor":"Aeras","startDate":"2014-02","conditions":"Tuberculosis","enrollment":989},{"nctId":"NCT03175380","phase":"EARLY_PHASE1","title":"Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US","status":"COMPLETED","sponsor":"Aeras","startDate":"2017-08-08","conditions":"Tuberculosis","enrollment":15},{"nctId":"NCT02202044","phase":"NA","title":"Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2015-02-24","conditions":"Bladder Carcinoma","enrollment":13},{"nctId":"NCT03790384","phase":"PHASE4","title":"Sequential Combination Therapy in Bladder Cancer","status":"UNKNOWN","sponsor":"Azienda Ospedaliera \"Sant'Andrea\"","startDate":"2019-01-15","conditions":"Bladder Cancer","enrollment":140},{"nctId":"NCT02444611","phase":"NA","title":"A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2015-03","conditions":"Innate Immune Response","enrollment":185},{"nctId":"NCT02420444","phase":"PHASE1","title":"A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults","status":"COMPLETED","sponsor":"Aeras","startDate":"2011-01","conditions":"Tuberculosis","enrollment":70},{"nctId":"NCT01119521","phase":"PHASE1","title":"Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-10","conditions":"Tuberculosis","enrollment":82},{"nctId":"NCT01007058","phase":"","title":"Markers of Response to Intravesical Bladder Cancer Therapy","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-06","conditions":"Bladder Cancer","enrollment":150},{"nctId":"NCT02311101","phase":"PHASE1","title":"Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2012-03","conditions":"Urinary Bladder Neoplasm","enrollment":18},{"nctId":"NCT02413502","phase":"EARLY_PHASE1","title":"Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naïve Healthy Adults in the US","status":"COMPLETED","sponsor":"Aeras","startDate":"2015-05","conditions":"Tuberculosis","enrollment":10},{"nctId":"NCT02207608","phase":"PHASE2","title":"Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"2011-09","conditions":"Poisoning by BCG Vaccine","enrollment":30},{"nctId":"NCT02254915","phase":"PHASE3","title":"SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I","status":"WITHDRAWN","sponsor":"Medical Enterprises Europe B.V.","startDate":"","conditions":"Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms","enrollment":""},{"nctId":"NCT00384891","phase":"PHASE3","title":"Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer","status":"TERMINATED","sponsor":"Medical Enterprises Europe B.V.","startDate":"2002-02","conditions":"Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urinary Bladder Cancer","enrollment":190},{"nctId":"NCT01442519","phase":"PHASE3","title":"Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"1994-01","conditions":"Bladder Cancer","enrollment":212}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5736,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BCG","BCG SSI"],"phase":"phase_3","status":"active","brandName":"Bacillus Calmette-Guérin (BCG)","genericName":"Bacillus Calmette-Guérin (BCG)","companyName":"Memorial Sloan Kettering Cancer Center","companyId":"memorial-sloan-kettering-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BCG is a live attenuated mycobacterial vaccine that stimulates the immune system to recognize and destroy cancer cells, particularly in the bladder. Used for Non-muscle-invasive bladder cancer (NMIBC), including carcinoma in situ, High-grade urothelial carcinoma of the bladder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}